MedTrace Logo

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

NCT06783647 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-05-18

No results posted yet for this study

Summary

An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.

Conditions

  • Advanced Solid Tumour

Interventions

DRUG

LBL-024 for Injection

intravenous infusion.

DRUG

Docetaxel Injection

intravenous infusion.

DRUG

Bevacizumab Injection

intravenous infusion.

DRUG

Pemetrexed Disodium for Injection

intravenous infusion.

DRUG

Paclitaxel Injection

intravenous infusion.

DRUG

Carboplatin Injection

intravenous infusion.

Sponsors & Collaborators

  • Sun Yat-Sen University Cancer Center

    collaborator OTHER

  • Nanjing Leads Biolabs Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • li Zhang · Sun Yat-Sen University Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-11
Primary Completion
2026-12-24
Completion
2026-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06783647 on ClinicalTrials.gov